Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)
Printer Friendly Page PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)

PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)

Clinicaltrials.gov identifier:
NCT05169437


Any advanced or metastatic solid tumor except ovarian or prostate

Study Contact Information:

Study Contact Information:
[email protected]


PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)

About the Study

PAVO is an Phase II study investigating if the study drug, a called (), is safe and effective for certain people who have been diagnosed with an advanced solid tumor with either an inherited or tumor mutation.

All participants will receive the study drug, . Study participants will be dosed with orally once daily throughout each 28-day cycle and be evaluated via CT or scans every 8 weeks for approximately one year. Participants will have the opportunity to report patient-reported outcomes (PROs) while on study treatment at the scan intervals.

This study is no longer enrolling people.

Study Locations

For a list of study sites enrolling patients, see clinicaltrials.gov.

Lead Researchers/Study PIs and Affiliation

 

This Study is Open To:

This study is no longer enrolling people.

This Study is Not Open To:

This study is no longer enrolling people.